{"ticker": {"uuid": "b385b32a-7f1c-46fb-a5d3-4b93421d5c05", "symbol": "EVMN", "name": "Evommune, Inc.", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Long term debt to total assets ratio of Evommune, Inc. \u2013 BX:EVMNUSD", "summary": "This article focuses on the long-term debt to total assets ratio of Evommune, Inc. (BX:EVMNUSD), providing financial data for the company. The content appears to be a financial data page from TradingView, without additional analytical text or detailed news. It simply presents the", "url": "https://www.tradingview.com/symbols/BX-EVMNUSD/financials-statistics-and-ratios/long-term-debt-to-assets/", "source_name": "TradingView", "published_at": "2026-07-21T05:10:14", "published_display": "21 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of \"Moderate Buy\" from Brokerages", "summary": "Evommune, Inc. (NYSE:EVMN) has received a \"Moderate Buy\" consensus rating from 14 brokerages, with an average 1-year price target of $45.63, despite a mixed outlook including one sell, three holds, eight buys, and two strong buys. The stock is trading near its 52-week low of $12.", "url": "https://www.marketbeat.com/instant-alerts/evommune-inc-nyseevmn-receives-consensus-rating-of-moderate-buy-from-brokerages-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T08:41:18", "published_display": "14 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Evommune (NYSE:EVMN) CFO Acquires 1,000 Shares of Stock", "summary": "Evommune's CFO, Kyle Carver, recently purchased 1,000 shares of the company's stock for $13.26 per share, totaling $13,260. This acquisition increased his direct holdings to 60,335 shares, following a sale of 18,175 shares in late May. The transaction occurred while EVMN shares w", "url": "https://www.marketbeat.com/instant-alerts/evommune-nyseevmn-cfo-acquires-1000-shares-of-stock-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-11T01:10:19", "published_display": "11 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune (NYSE:EVMN) Director Acquires $133,000.00 in Stock", "summary": "Evommune (NYSE:EVMN) Director Arthur Kirsch recently purchased 10,000 shares of the company's stock for $133,000, bringing his total ownership to 10,000 shares. This transaction occurred on July 7th at an average price of $13.30 per share. Despite the insider buying, EVMN shares ", "url": "https://www.marketbeat.com/instant-alerts/evommune-nyseevmn-director-acquires-13300000-in-stock-2026-07-08/", "source_name": "MarketBeat", "published_at": "2026-07-09T01:10:01", "published_display": "09 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky", "summary": "Levi & Korsinsky is investigating potential securities fraud claims against Evommune, Inc. (EVMN) on behalf of its shareholders. The investigation focuses on whether the company or its officers engaged in misleading business practices. Shareholders who suffered losses are encoura", "url": "https://www.moomoo.com/news/post/72600742/evommune-inc-evmn-securities-fraud-investigation-levi-korsinsky", "source_name": "Moomoo", "published_at": "2026-07-08T03:10:01", "published_display": "08 Jul 2026 03:10", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $54", "summary": "Stifel has reiterated its Buy rating for Evommune (EVMN.US) and maintained a target price of $54. This indicates a continued positive outlook from the financial firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72500323/stifel-maintains-evommune-evmnus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-07-06T11:10:59", "published_display": "06 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune\u2019s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market", "summary": "Evommune, Inc. announced the completion of its Phase 2b trial for EVO756, an oral drug designed to treat moderate to severe chronic spontaneous urticaria. This milestone is crucial for investors as positive results could pave the way for a larger Phase 3 program and potential par", "url": "https://www.tipranks.com/news/company-announcements/evommunes-evo756-trial-completion-signals-key-milestone-in-chronic-urticaria-market", "source_name": "TipRanks", "published_at": "2026-07-01T16:10:50", "published_display": "01 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune\u2019s Healthy Balance Sheet Buys Them Time For AD (NYSE:EVMN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPZTFOQ0VOY2pSNzhfZ1ZaNE0wb1JLbUh2cC1fSlZsbzVGNmNOWHZDT2Z5MjlmMTRlTzBUWDV1bEFaaW03SC1oNzVYQXQ3YjZHVU5xWjJtQ0ltOUl6S0s3U3lSZmFQWjB5UnZlRGZJQVkyMVpxYm1pWTc2NTFOSXdkcHFIdVpBVElIY3hjdzJHcTJ2eUwyWDFRR0NYRkpsUG5D?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oral CSU Drug Falls Short in Phase 2b Study; Evommune Ends Development", "summary": "Evommune, Inc.'s oral MRGPRX2 antagonist, EVO756, failed to meet its primary endpoint in a Phase 2b trial for chronic spontaneous urticaria (CSU), leading the company to discontinue its development for this indication. Despite this setback, Evommune plans to continue evaluating E", "url": "https://thedermdigest.com/oral-csu-drug-falls-short-in-phase-2b-study-evommune-ends-development/", "source_name": "The Dermatology Digest", "published_at": "2026-06-30T21:39:52", "published_display": "30 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)", "summary": "Levi & Korsinsky, LLP has initiated an investigation into the officers and directors of Evommune, Inc. (EVMN) following a significant stock drop. This investigation concerns insider stock sales by the CEO and CSO that occurred just days before the company publicly announced that ", "url": "https://www.prnewswire.com/news-releases/evommune-inc-investigation-initiated-levi--korsinsky-investigates-the-officers-and-directors-of-evommune-inc-evmn-302814776.html", "source_name": "PR Newswire", "published_at": "2026-06-30T17:41:03", "published_display": "30 Jun 2026 17:41", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune (NYSE: EVMN) halts EVO756 CSU program after Phase 2b miss", "summary": "Evommune (NYSE: EVMN) announced the discontinuation of its EVO756 program for chronic spontaneous urticaria (CSU) following a Phase 2b trial failure. The study, which enrolled 160 patients, did not meet its primary endpoint of mean change in Urticaria Activity Score over seven da", "url": "https://www.stocktitan.net/sec-filings/EVMN/424b3-evommune-inc-prospectus-filed-pursuant-to-rule-424-b-3-b7bdd0ac6afb.html", "source_name": "Stock Titan", "published_at": "2026-06-30T01:09:13", "published_display": "30 Jun 2026 01:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EVO756 trial miss, Evommune (NYSE: EVMN) shifts focus to AD and migraine", "summary": "Evommune (NYSE: EVMN) announced that its oral drug EVO756 failed to meet its primary endpoint in a Phase 2b trial for chronic spontaneous urticaria (CSU), leading the company to halt further development for that indication. Despite this setback, Evommune will continue evaluating ", "url": "https://www.stocktitan.net/sec-filings/EVMN/8-k-evommune-inc-reports-material-event-94af3d7a2a2f.html", "source_name": "Stock Titan", "published_at": "2026-06-30T00:10:24", "published_display": "30 Jun 2026 00:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune, Inc. Stock 12\u2011Month Price Target Cut to $39.33, Implies 56% Upside", "summary": "Evommune, Inc. (EVMN) has seen its average 12-month price target reduced from $45.22 to $39.33 by analysts, though this new target still suggests approximately 56% potential upside from the June 26 closing price. The consensus rating for the stock remains a \"Buy\" from 11 analysts", "url": "https://www.tradingview.com/news/tradingview:a625d7dc96eff:0-evommune-inc-stock-12-month-price-target-cut-to-39-33-implies-56-upside/", "source_name": "TradingView", "published_at": "2026-06-29T22:20:04", "published_display": "29 Jun 2026 22:20", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune, Inc.(NYSE: EVMN) dropped from Russell 2000 Value Benchmark", "summary": "Evommune, Inc. (NYSE: EVMN), a clinical-stage biotechnology company, has been removed from the Russell 2000 Value Benchmark, alongside being dropped from several other Russell indices. This news coincides with recent reports of the company's EVO756 Phase 2b trial in chronic spont", "url": "https://www.marketscreener.com/news/evommune-inc-nyse-evmn-dropped-from-russell-2000-value-benchmark-ce7f5fdfda8bf02c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:12:05", "published_display": "29 Jun 2026 18:12", "sentiment": "negative", "sentiment_pct": 16, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria", "summary": "Evommune, Inc. announced that its Phase 2b trial for EVO756 in moderate-to-severe chronic spontaneous urticaria (CSU) did not meet its primary endpoint. Despite this, the company plans to continue developing EVO756 for atopic dermatitis and migraine, with top-line data for atopic", "url": "https://www.businesswire.com/news/home/20260629470075/en/Evommune-Announces-Top-line-Results-from-EVO756-Phase-2b-Trial-in-Moderate-to-Severe-Chronic-Spontaneous-Urticaria", "source_name": "Business Wire", "published_at": "2026-06-29T12:12:04", "published_display": "29 Jun 2026 12:12", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Companies Like Evommune (NYSE:EVMN) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNal9FS1NUVWpaRUNpWHZUc1BfcGFhU0gwYkpTTzRlaER5azF3V0VvaVBWa1lsTlJ3TjhvMXpJMTNTTDZRWGZybWhWeFhpT2NLWW4zR0JSQlkzUWJ5YXZGd3kwSEgwLVR1V0lZUHN6QmZHUDM0a3FCYTl2VTBGSFI2OXRGVS1ybERhWV9jLUxIWjVzdE9GX1hMUW5Pam9QRUIwdzJEYQ?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Evommune (EVMN) Valuation After Strong Phase 2a Eczema Data And US$125.3m Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNR2dNRnBzUUFXVklickVlc1hZaWd4MDMxb2pvS1Jsbi04TFFUQ2FqTFo5MU85elpsNG51SklwazBvSnFITElpdkN3OFdaX2FwbktnYnZzT3RDbFY0ZDJINFBqNFVsaE1fbjlJME94TGxlVDA1NWlQQWRmOHhhcXVVQklBTE90SXBlVHR3TG5wNA?oc=5", "source_name": "Market source", "published_at": "2026-02-14T08:00:00+00:00", "published_display": "14 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Long term debt to total assets ratio of Evommune, Inc. \u2013 BX:EVMNUSD", "summary": "This article focuses on the long-term debt to total assets ratio of Evommune, Inc. (BX:EVMNUSD), providing financial data for the company. The content appears to be a financial data page from TradingView, without additional analytical text or detailed news. It simply presents the", "url": "https://www.tradingview.com/symbols/BX-EVMNUSD/financials-statistics-and-ratios/long-term-debt-to-assets/", "source_name": "TradingView", "published_at": "2026-07-21T05:10:14", "published_display": "21 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of \"Moderate Buy\" from Brokerages", "summary": "Evommune, Inc. (NYSE:EVMN) has received a \"Moderate Buy\" consensus rating from 14 brokerages, with an average 1-year price target of $45.63, despite a mixed outlook including one sell, three holds, eight buys, and two strong buys. The stock is trading near its 52-week low of $12.", "url": "https://www.marketbeat.com/instant-alerts/evommune-inc-nyseevmn-receives-consensus-rating-of-moderate-buy-from-brokerages-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T08:41:18", "published_display": "14 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune (NYSE:EVMN) CFO Acquires 1,000 Shares of Stock", "summary": "Evommune's CFO, Kyle Carver, recently purchased 1,000 shares of the company's stock for $13.26 per share, totaling $13,260. This acquisition increased his direct holdings to 60,335 shares, following a sale of 18,175 shares in late May. The transaction occurred while EVMN shares w", "url": "https://www.marketbeat.com/instant-alerts/evommune-nyseevmn-cfo-acquires-1000-shares-of-stock-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-11T01:10:19", "published_display": "11 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune (NYSE:EVMN) Director Acquires $133,000.00 in Stock", "summary": "Evommune (NYSE:EVMN) Director Arthur Kirsch recently purchased 10,000 shares of the company's stock for $133,000, bringing his total ownership to 10,000 shares. This transaction occurred on July 7th at an average price of $13.30 per share. Despite the insider buying, EVMN shares ", "url": "https://www.marketbeat.com/instant-alerts/evommune-nyseevmn-director-acquires-13300000-in-stock-2026-07-08/", "source_name": "MarketBeat", "published_at": "2026-07-09T01:10:01", "published_display": "09 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky", "summary": "Levi & Korsinsky is investigating potential securities fraud claims against Evommune, Inc. (EVMN) on behalf of its shareholders. The investigation focuses on whether the company or its officers engaged in misleading business practices. Shareholders who suffered losses are encoura", "url": "https://www.moomoo.com/news/post/72600742/evommune-inc-evmn-securities-fraud-investigation-levi-korsinsky", "source_name": "Moomoo", "published_at": "2026-07-08T03:10:01", "published_display": "08 Jul 2026 03:10", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $54", "summary": "Stifel has reiterated its Buy rating for Evommune (EVMN.US) and maintained a target price of $54. This indicates a continued positive outlook from the financial firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72500323/stifel-maintains-evommune-evmnus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-07-06T11:10:59", "published_display": "06 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune\u2019s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market", "summary": "Evommune, Inc. announced the completion of its Phase 2b trial for EVO756, an oral drug designed to treat moderate to severe chronic spontaneous urticaria. This milestone is crucial for investors as positive results could pave the way for a larger Phase 3 program and potential par", "url": "https://www.tipranks.com/news/company-announcements/evommunes-evo756-trial-completion-signals-key-milestone-in-chronic-urticaria-market", "source_name": "TipRanks", "published_at": "2026-07-01T16:10:50", "published_display": "01 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune\u2019s Healthy Balance Sheet Buys Them Time For AD (NYSE:EVMN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPZTFOQ0VOY2pSNzhfZ1ZaNE0wb1JLbUh2cC1fSlZsbzVGNmNOWHZDT2Z5MjlmMTRlTzBUWDV1bEFaaW03SC1oNzVYQXQ3YjZHVU5xWjJtQ0ltOUl6S0s3U3lSZmFQWjB5UnZlRGZJQVkyMVpxYm1pWTc2NTFOSXdkcHFIdVpBVElIY3hjdzJHcTJ2eUwyWDFRR0NYRkpsUG5D?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oral CSU Drug Falls Short in Phase 2b Study; Evommune Ends Development", "summary": "Evommune, Inc.'s oral MRGPRX2 antagonist, EVO756, failed to meet its primary endpoint in a Phase 2b trial for chronic spontaneous urticaria (CSU), leading the company to discontinue its development for this indication. Despite this setback, Evommune plans to continue evaluating E", "url": "https://thedermdigest.com/oral-csu-drug-falls-short-in-phase-2b-study-evommune-ends-development/", "source_name": "The Dermatology Digest", "published_at": "2026-06-30T21:39:52", "published_display": "30 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)", "summary": "Levi & Korsinsky, LLP has initiated an investigation into the officers and directors of Evommune, Inc. (EVMN) following a significant stock drop. This investigation concerns insider stock sales by the CEO and CSO that occurred just days before the company publicly announced that ", "url": "https://www.prnewswire.com/news-releases/evommune-inc-investigation-initiated-levi--korsinsky-investigates-the-officers-and-directors-of-evommune-inc-evmn-302814776.html", "source_name": "PR Newswire", "published_at": "2026-06-30T17:41:03", "published_display": "30 Jun 2026 17:41", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune (NYSE: EVMN) halts EVO756 CSU program after Phase 2b miss", "summary": "Evommune (NYSE: EVMN) announced the discontinuation of its EVO756 program for chronic spontaneous urticaria (CSU) following a Phase 2b trial failure. The study, which enrolled 160 patients, did not meet its primary endpoint of mean change in Urticaria Activity Score over seven da", "url": "https://www.stocktitan.net/sec-filings/EVMN/424b3-evommune-inc-prospectus-filed-pursuant-to-rule-424-b-3-b7bdd0ac6afb.html", "source_name": "Stock Titan", "published_at": "2026-06-30T01:09:13", "published_display": "30 Jun 2026 01:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EVO756 trial miss, Evommune (NYSE: EVMN) shifts focus to AD and migraine", "summary": "Evommune (NYSE: EVMN) announced that its oral drug EVO756 failed to meet its primary endpoint in a Phase 2b trial for chronic spontaneous urticaria (CSU), leading the company to halt further development for that indication. Despite this setback, Evommune will continue evaluating ", "url": "https://www.stocktitan.net/sec-filings/EVMN/8-k-evommune-inc-reports-material-event-94af3d7a2a2f.html", "source_name": "Stock Titan", "published_at": "2026-06-30T00:10:24", "published_display": "30 Jun 2026 00:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune, Inc. Stock 12\u2011Month Price Target Cut to $39.33, Implies 56% Upside", "summary": "Evommune, Inc. (EVMN) has seen its average 12-month price target reduced from $45.22 to $39.33 by analysts, though this new target still suggests approximately 56% potential upside from the June 26 closing price. The consensus rating for the stock remains a \"Buy\" from 11 analysts", "url": "https://www.tradingview.com/news/tradingview:a625d7dc96eff:0-evommune-inc-stock-12-month-price-target-cut-to-39-33-implies-56-upside/", "source_name": "TradingView", "published_at": "2026-06-29T22:20:04", "published_display": "29 Jun 2026 22:20", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune, Inc.(NYSE: EVMN) dropped from Russell 2000 Value Benchmark", "summary": "Evommune, Inc. (NYSE: EVMN), a clinical-stage biotechnology company, has been removed from the Russell 2000 Value Benchmark, alongside being dropped from several other Russell indices. This news coincides with recent reports of the company's EVO756 Phase 2b trial in chronic spont", "url": "https://www.marketscreener.com/news/evommune-inc-nyse-evmn-dropped-from-russell-2000-value-benchmark-ce7f5fdfda8bf02c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:12:05", "published_display": "29 Jun 2026 18:12", "sentiment": "negative", "sentiment_pct": 16, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria", "summary": "Evommune, Inc. announced that its Phase 2b trial for EVO756 in moderate-to-severe chronic spontaneous urticaria (CSU) did not meet its primary endpoint. Despite this, the company plans to continue developing EVO756 for atopic dermatitis and migraine, with top-line data for atopic", "url": "https://www.businesswire.com/news/home/20260629470075/en/Evommune-Announces-Top-line-Results-from-EVO756-Phase-2b-Trial-in-Moderate-to-Severe-Chronic-Spontaneous-Urticaria", "source_name": "Business Wire", "published_at": "2026-06-29T12:12:04", "published_display": "29 Jun 2026 12:12", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Evommune (NYSE:EVMN) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNal9FS1NUVWpaRUNpWHZUc1BfcGFhU0gwYkpTTzRlaER5azF3V0VvaVBWa1lsTlJ3TjhvMXpJMTNTTDZRWGZybWhWeFhpT2NLWW4zR0JSQlkzUWJ5YXZGd3kwSEgwLVR1V0lZUHN6QmZHUDM0a3FCYTl2VTBGSFI2OXRGVS1ybERhWV9jLUxIWjVzdE9GX1hMUW5Pam9QRUIwdzJEYQ?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Evommune (EVMN) Valuation After Strong Phase 2a Eczema Data And US$125.3m Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNR2dNRnBzUUFXVklickVlc1hZaWd4MDMxb2pvS1Jsbi04TFFUQ2FqTFo5MU85elpsNG51SklwazBvSnFITElpdkN3OFdaX2FwbktnYnZzT3RDbFY0ZDJINFBqNFVsaE1fbjlJME94TGxlVDA1NWlQQWRmOHhhcXVVQklBTE90SXBlVHR3TG5wNA?oc=5", "source_name": "Market source", "published_at": "2026-02-14T08:00:00+00:00", "published_display": "14 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 26, "sentiment_summary": {"positive": 6, "negative": 8, "neutral": 12, "score": 43, "total": 26, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 73, "events": [{"event": "earnings", "label": "Earnings", "weight": 4.81, "count": 11}, {"event": "general", "label": "Market update", "weight": 4.75, "count": 8}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 12.14, "latest_week": "2026-07-17", "one_week_move": -8.1, "four_week_move": -43.2, "twelve_week_move": -52.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.737205, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": -42.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "positive", "expectation_probability": 65.0718, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.1% over one week, -43.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "TradingView", "count": 3}, {"label": "MarketBeat", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "Stock Titan", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "TipRanks", "count": 1}, {"label": "Seeking Alpha", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 17}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 11}, {"label": "Market update", "count": 8}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "43/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "73/100 classification confidence."}, {"label": "Company focus", "value": "17", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-8.1% over one week, -43.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Long term debt to total assets ratio of Evommune, Inc. \u2013 BX:EVMNUSD"}], "updated_at": "2026-07-23T20:03:38.436856+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}